MagnetisMM-5
Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 944 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1170
- NCT Identifier
- NCT05020236
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.